Lexeo Therapeutics officer proposes $10.7K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Richard N. Townsend, a Lexeo Therapeutics, Inc. (LXEO) officer and director, reported a proposed sale of 3,295 common shares, with an approximate sale date of November 17, 2026 and an aggregate market value of $10,741.04. He acquired the shares from the issuer on November 16, 2026 through restricted stock vesting as compensation. Townsend’s remarks say the sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution.
Key Figures
Key Terms
Restricted Stock Vesting financial
vested equity award distribution financial
aggregate market value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.